Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
Thu, 15.08.2024
DEMIRE Deutsche Mittelstand Real Estate AG
Agreement between DEMIRE and creditors with bond volume of 90 % now formalised
Formal process to amend the terms and conditions of the bond in accordance with the German Bond Act (Schuldverschreibungsgesetz) has started
Significant reduction of the LTV to around 40% possible after completion of the refinancing
Langen, 15 August 2024. DEMIRE Deut [ … ]
Thu, 15.08.2024
Northern Data AG
PRESS RELEASE / IR NEWS
Northern Data Group CEO Aroosh Thillainathan initiates another standing order for share acquisition
Transaction amounts to a total purchase price of up to EUR 10 million over the next two months
Acquisition expected to increase the CEOs stake to more than 8.0% of Northern Data Group’s share capital. Purchase follows a su [ … ]
Thu, 15.08.2024
CureVac
CureVac Announces Financial Results for the Second Quarter and First Half of 2024and Provides Business Update
Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac’s mRNA platform
Initiated strategic workforce reduction of ~30% by end of 2024, optimizing business [ … ]
Thu, 15.08.2024
CureVac
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM
Part B expected to include up to 20 patients to generate extended data on safety, tolerability, an [ … ]
Thu, 15.08.2024
CureVac
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
TÜBINGEN, Germany/BOSTON, USA – August 15, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today named clinical oncologist [ … ]
Thu, 15.08.2024
EcoGraf Limited
EcoGraf
ASX Release / 15 August 2024
Epanko Graphite Processing Plant Layout Design Completed
Pre-Development Infrastructure Drilling Works Commenced
EcoGraf Limited (ASX: EGR; FSE: FMK; OTCQB: ECGFF) is pleased to announce the completion of the final layout design for the 73,000tpa graphite processing plant by METC Engineering and Construction [ … ]
Thu, 15.08.2024
USU Software AG
Möglingen, August 15, 2024.
The US-based analyst firm Forrester has published the report “The Knowledge Management Solutions Landscape Q3 2024,” in which USU is listed as one of the notable vendors. The overview offers a comprehensive analysis of the current market for knowledge management (KM) solutions. USU is recognized as one of 20 notable KM [ … ]
Thu, 15.08.2024
BayWa AG
BayWa AG today concluded standstill agreements with its main lending banks and a bridging loan agreement with a core group of banks amounting to €272 million. The agreements are initially valid until 30 September 2024, with the option of an extension until 31 December 2024.
As a key component of the overall stabilisation concept, BayWa AG’s two la [ … ]
Thu, 15.08.2024
MLP SE
Company Name:
MLP SE
ISIN:
DE0006569908
Reason for the research:
Update
Recommendation:
BUY
from:
15.08.2024
Target price:
EUR 11.50
Last rating change:
Analyst:
Henry Wendisch
Solid Q2 driven by wealth management and banking
Topic: Following preliminary EBIT results from 29th July (see update from 30th July), MLP provided more [ … ]
Thu, 15.08.2024
VOQUZ Labs AG
Company Name:
VOQUZ Labs AG
ISIN:
DE000A3CSTW4
Reason for the research:
Update
Recommendation:
BUY
from:
15.08.2024
Target price:
EUR 22.00
Last rating change:
Analyst:
Philipp Sennewald
H1 prelims display strong yoy improvements; chg.
Topic: VOQUZ Labs released preliminary H1 results, which show significant improvements in top [ … ]